ArticlePharmaceutical research2003
Large porous particle impingement on lung epithelial cell monolayers--toward improved particle characterization in the lung.
Article in Pharmaceutical research, 2003. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 27 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
27 citing papers in PubMed.
- Intranasal Application of Peptides Modulating the Neuropeptide Y System.ACS pharmacology & translational science · 2025Article
- Impact of mucus modulation byInternational journal of pharmaceutics: X · 2023Article
- Optimization of ionizable lipids for aerosolizable mRNA lipid nanoparticles.Bioengineering & translational medicine · 2023Article
- Human 3D Airway Tissue Models for Real-Time Microscopy: Visualizing Respiratory Virus Spreading.Cells · 2022Article
- Preparation and Evaluation of Mucus-Penetrating Inhalable Microparticles of Tiotropium Bromide Containing Sodium Glycocholate.Pharmaceutics · 2022Article
- Human Multi-CompartmentFrontiers in physiology · 2022Article
- A comparison of three mucus-secreting airway cell lines (Calu-3, SPOC1 and UNCN3T) for use as biopharmaceutical models of the nose and lung.European journal of pharmaceutics and biopharmaceutics : official journal of Arbeitsgemeinschaft fur Pharmazeutische Verfahrenstechnik e.V · 2021Article
- Air-liquid interface cultures of the healthy and diseased human respiratory tract: promises, challenges and future directions.Advanced nanobiomed research · 2021Article
- PerfuPul-A Versatile Perfusable Platform to Assess Permeability and Barrier Function of Air Exposed Pulmonary Epithelia.Frontiers in bioengineering and biotechnology · 2021Article
- Lung cell exposure to secondary photochemical aerosols generated from OH oxidation of cyclic siloxanes.Chemosphere · 2020Article
- Review
- Immunomodulatory effects of a low-dose clarithromycin-based macrolide solution pressurised metered dose inhaler.Pharmaceutical research · 2015Article
- Permeation of Therapeutic Drugs in Different Formulations across the Airway Epithelium In Vitro.PloS one · 2015Article
- In vitro cell integrated impactor deposition methodology for the study of aerodynamically relevant size fractions from commercial pressurised metered dose inhalers.Pharmaceutical research · 2014Article
- Polymeric nanocarriers for transport modulation across the pulmonary epithelium: dendrimers, polymeric nanoparticles, and their nanoblends.The AAPS journal · 2014Article
- Drug delivery characteristics of the progenitor bronchial epithelial cell line VA10.Pharmaceutical research · 2013Article
- Comparison of two in vitro systems to assess cellular effects of nanoparticles-containing aerosols.Toxicology in vitro : an international journal published in association with BIBRA · 2013Article
- Inhaled chemotherapy in lung cancer: future concept of nanomedicine.International journal of nanomedicine · 2012Review
- The effect of liposome encapsulation on the pharmacokinetics of recombinant secretory leukocyte protease inhibitor (rSLPI) therapy after local delivery to a guinea pig asthma model.Pharmaceutical research · 2011Article
- Epithelial profiling of antibiotic controlled release respiratory formulations.Pharmaceutical research · 2011Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeThe ability to optimize new formulations for pulmonary delivery has been limited by inadequate in vitro models used to mimic conditions particles encounter in the lungs. The aim is to develop a physiologically-relevant model of the pulmonary epithelial barrier that would allow for quantitative characterization of therapeutic aerosols in vitro.
methodsCalu-3 human bronchial epithelial cells were cultured on permeable filter inserts under air-interfaced culture (AIC) and liquid-covered culture (LCC) conditions. Calu-3 cells grown under both conditions formed tight monolayers and appeared physiologically similar by SEM and immunocytochemical staining against cell junctional proteins and prosurfactant protein-C.
resultsAerosolized large porous particles (LPP) deposited homogeneously and reproducibly on the cell surface and caused no apparent damage to cell monolayers by SEM and light microscopy. However, monolayers initially grown under LCC conditions showed a significant decrease in barrier properties within the first 90 min after impingement with microparticles, as determined by transepithelial electrical resistance (TEER) measurements and fluorescein-sodium transport. Conversely, AIC grown monolayers showed no significant change in barrier properties within the first 90 min following particle application. A dense mucus coating was found on AIC grown Calu-3 monolayers, but not on LCC grown monolayers, which may protect the cell surface during particle impinging.
conclusionThis in vitro model, based on AIC grown Calu-3 cells, should allow a more relevant and quantitative characterization of therapeutic aerosol particles intended for delivery to the tracheobronchial region of the lung or to the nasal passages. Such characterization is likely to be particularly important with therapeutic aerosol particles designed to provide sustained drug release in the lung.
Indexed as
Identifiers
12751635What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.